Sean Duffy has already raised hundreds of millions of dollars for his enterprise health company that is blending technology, behavior science, and medicine together. 

On the Dealmakers Show Duffy talked about providing virtual care, innovating in the rigid and highly regulated US healthcare system, making sales at the enterprise level, managing boards, and leadership.

Read More: https://alejandrocremades.com/this-entrepreneur-raised-over-450-million-to-deliver-virtual-chronic-care-solutions/

A less invasive procedure to reduce the risk of stroke by clearing blockages of the carotid artery in the neck is being offered more widely as a result of recent approval by the Food & Drug Administration.
The procedure, called transcarotid artery revascularization, or TCAR, employs the unusual technique of temporarily reversing the flow of blood away from the brain in order to reduce the risk of stroke during and after the surgery.
Previously, this relatively new endovascular approach was reserved by the FDA for only a small subset of patients. However, several years of data has shown it is as safe and successful as the more traditional endarterectomy “open surgery,” while also offering the benefits of a quicker recovery, smaller incision and reduced risk of nerve injury.

Read More: https://baptisthealth.net/baptist-health-news/going-against-the-flow-innovative-tcar-procedure-lowers-stroke-risk/

One of the most frustrating things for our patients who had a stroke is the inability to perform activities of daily living because of the weakness of the upper limb.

The current therapies we prescribe are quite limited. Many of these therapies have not been shown to induce the neuroplastic changes important for long-lasting recovery.

We are excited to offer our patients the Vivistim® System to magnify their potential to recover further.

Read More: ​https://www.linkedin.com/posts/microtransponder_rehabilitationawarenessweek-powerofmedicalrehab-activity-6978029271642456064-zlCA/?utm_source=share&utm_medium=member_desktop

We’re thrilled to announce that Hinge Health has been recognized in Employee Benefit News's 2022 Excellence in Benefits Awards! It's a reflection of Karen Stander, FACHE, Inessa Lurye, and the whole women’s pelvic health team's tireless work over the past year to help address the benefits gap that many women face when it comes to pelvic floor disorders. We’re proud to be a part of the conversation that advances the narrative around a condition that one in four women are silently suffering from: https://lnkd.in/dQHnYaFr

This week neurosurgeon Dr. Peter Warnke and his team [at UChicago Medicine] successfully completed the first vagus nerve stimulation implantation procedure in the Midwest. Paired with rehabilitation this implant can help patients who have suffered from a stroke regain hand and arm movements.

Read More: https://www.linkedin.com/posts/microtransponder_this-week-neurosurgeon-dr-peter-warnke-activity-6974009311421202432-cALU/?utm_source=share&utm_medium=member_desktop

The randomized controlled multicenter study is the first-of-its kind to investigate LITT benefits in radiographically recurrent brain metastasis patients
MINNETONKA, Minn. – Sept. 7, 2022 – Monteris Medical announced today that the first patient has been enrolled in its REMASTer (Recurrent Brain Metastases After Stereotactic Radiosurgery [SRS] Trial) clinical trial. This randomized controlled study is designed to investigate laser interstitial thermal therapy (LITT) using the NeuroBlate System as an early intervention for radiographically progressive brain metastases and to provide Level I evidence to guide treatment for this complex patient population.
Treatment of recurrent brain metastases is challenging as no standardized care currently exists within the clinical community for patients with disease progression following SRS. This is primarily attributed to the uncertainty of the underlying cause being either recurrence or radiation necrosis. In recent years, LITT has proved to be an effective tool for both causes of progression after SRS and can be performed during the same procedure as needle biopsy. Recent published studies suggest that LITT plus SRS may be superior to LITT alone or repeat SRS alone for treatment of biopsy-proven brain metastasis recurrence after SRS failure, even after controlling for variables known to predict progression. Recent literature also has revealed LITT to be effective for the treatment of radiation necrosis, with a superior time to steroid independence compared to medical management alone.
The REMASTer trial is designed to determine the superior treatment algorithm for both the recurrent tumor and radiation necrosis populations. The study will enroll 154 patients at up to 12 sites. Primary endpoints for the study include time to local intracranial progression or death and time to steroid cessation. Additional endpoints include comparison of treatment approaches with respect to overall survival, quality of life, and cognitive changes over time.

Read More: ​https://www.monteris.com/press-releases/monteris-medical-announces-first-patient-enrolled-in-remaster-clinical-study-on-neuroblate-system-for-metastatic-brain-tumor-patients/

Read More: ​https://finance.yahoo.com/news/silk-road-medical-announces-first-201500112.html

Amazon recently sent shock waves through healthcare when they announced their $3.9 billion acquisitionopens in a new tab or window of One Medical. This follows its 2018 acquisition of PillPack and 2019 Amazon Care launch. With $29 billion of venture investmentopens in a new tab or window into digital health in 2021, this may seem like just another headline -- but we feel this one is different.

In placing their bet on a primary care network that delivers a hybrid of in-person and virtual care, Amazon chose a path that positions it to be a front-runner in primary care innovation.

​Read More: ​https://www.medpagetoday.com/opinion/second-opinions/100373?utm_source=Linkedin&utm_medium=Organic%20Social&utm_campaign=&utm_term=&utm_content=

Yesterday, in groundbreaking #kidneycare news, the American Heart Association issued a statement in support of home dialysis over in-center dialysis for patients with kidney and cardiovascular disease, citing cardiovascular co-morbidities and poor outcomes from thrice-weekly in-center hemodialysis, which is currently the most common therapy performed worldwide. 

Read More: ​https://www.linkedin.com/posts/outset-medical_american-heart-association-endorses-home-activity-6971854721879834624-lHCi